Innovate

科学创新

HJC黄金城拥有完整细胞药物开发平台，满足多种临床需求

STAR-T平台

具有自主知识产权的合成性T细胞受体抗原受体( Synthetic TCR and Antigen Receptor), STAR-T细胞治疗技术平台。
与当前细胞治疗领域常用的CAR-T技术相比，STAR-T更具有天然T细胞的特性，具有天然双靶点，毒性低，耗竭慢，浸润性强的特点，更有可能实现对实体瘤治疗的突破。

Capa平台

自研的Capa (CasRNP-pseudotyped AAV editing system)是一种基因编辑 T细胞的颠覆性突破技术，可通过非电转体系在指定位点插入目的基因，该技术对T细胞损伤小、易于工业化放大、成本低。
其结合STAR平台的定点整合可代偿内源TCR被敲除的缺陷，开发革命性的通用型T细胞产品。

相关新闻和发表文章

[1]A Feasibility and Safety Study of a Novel CD19-Directed Synthetic T-Cell Receptor and Antigen Receptor (STAR) T-Cell Therapy for Refractory and Relapsed (R/R) B Cell Acute Lymphoblastic Leukemia (B-ALL). Blood. November 5, 2020.

[2]Phase 1 study shows feasibility, safety, efficacy of STAR T cells for ALL. Hematology News. December 14, 2020.

[3]Chimeric STAR receptors using TCR machinery mediate robust responses against solid tumors.Sci Transl Med. Mar 24,2021.

[4]A Novel CMV-Specific TCR-T Cell Therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation. ASH Meeting. December 13, 2021.

[5]A novel CD19/CD20 dual synthetic T-cell receptor and antigen receptor (STAR) T cell therapy for refractory and relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL). EHA Library.. 06/09/2021; 324526; S118.

[6] A novel adoptive synthetic TCR and antigen receptor (STAR) T-Cell therapy for B-Cell acute lymphoblastic leukemia. American Journal of Hematology.01 May 2022